Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methylprednisolone sodium succinate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methylprednisolone sodium succinate -

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see clinical considerations). in animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryofetal toxicity at doses less tha

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 20 mg - propranolol hydrochloride tablets are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. pr

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 40 mg - propranolol hydrochloride tablets are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. pr

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 20 mg - propranolol hydrochloride tablets are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. pr

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - sapropterin dihydrochloride, quantity: 100 mg - tablet, soluble - excipient ingredients: sodium stearylfumarate; calcium hydrogen phosphate; mannitol; crospovidone; ascorbic acid; riboflavin - kuvan is indicated for the treatment of hyperphenylalaninemia (hpa) in sapropterin-responsive adult and paediatric patients with phenylketonuria (pku) or tetrahydrobiopterin (bh4) deficiency (see section 4.2 dose and method of administration for definition of sapropterin responsiveness)

United States - English - NLM (National Library of Medicine)

direct rx - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastroparesis (

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 150 mg - tramadol hydrochloride extended-release is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. tramadol hydrochloride extended-release is contraindicated in patients who have previously demonstrated hypersensitivity to tramadol, any other component of tramadol hydrochloride extended-release, or opioids. reactions range from pruritis to fatal anaphylactoid reactions [see warnings and precautions (5.4)]. tramadol hydrochloride extended-release is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. tramadol hydrochloride extended-release is contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment. teratogenic effects: pregnancy category c there are no adequate and well-controlled studies in pregnant women. use tramadol hydroch

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - based on a review of this drug by the national academy of sciences — national research council and/or other information, fda has classified the indications as follows: "possibly" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. final classification of the less-than-effective indications requires further investigation. chlordiazepoxide hcl/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt disc